Beijing Pilots First Provincial Fast-Track Regulation To Cover More Innovative Drugs
This article was originally published in PharmAsia News
Drugs from multinationals could be eligible under the new program, experts say.
You may also be interested in...
China's Center For Drug Evaluation Remakes Itself To Enter New Era Of Transparency, Speed Up Approvals
China Issues Fast-Track Registration Procedure For Drugs To Balance Innovation And Risk: SFDA Press Conference
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.